Allspring Global Investments Holdings LLC Sells 19,388 Shares of LivaNova PLC $LIVN

Allspring Global Investments Holdings LLC lowered its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 9.6% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 182,444 shares of the company’s stock after selling 19,388 shares during the period. Allspring Global Investments Holdings LLC’s holdings in LivaNova were worth $11,791,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after buying an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after buying an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in LivaNova by 10.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after buying an additional 15,405 shares in the last quarter. Intech Investment Management LLC grew its position in LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after acquiring an additional 7,195 shares during the last quarter. Finally, Strs Ohio bought a new position in LivaNova during the first quarter valued at approximately $130,000. 97.64% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.35% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LIVN. KeyCorp upped their price objective on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Barclays boosted their price target on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Mizuho raised their price objective on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Freedom Capital raised LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.38.

LivaNova Trading Up 0.8%

Shares of LIVN opened at $79.85 on Wednesday. The stock has a market capitalization of $4.39 billion, a P/E ratio of 40.95 and a beta of 0.86. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $85.27. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The firm has a fifty day simple moving average of $77.89 and a two-hundred day simple moving average of $69.24.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, research analysts anticipate that LivaNova PLC will post 3.73 EPS for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.